Compare RUN & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUN | IRON |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.9B |
| IPO Year | 2015 | 2020 |
| Metric | RUN | IRON |
|---|---|---|
| Price | $9.59 | $78.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 11 |
| Target Price | $18.80 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 9.7M | 492.5K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 113.35 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $858,578,000.00 | N/A |
| Revenue This Year | $2.81 | N/A |
| Revenue Next Year | $4.54 | $283.52 |
| P/E Ratio | $15.35 | ★ N/A |
| Revenue Growth | ★ 12.97 | N/A |
| 52 Week Low | $9.01 | $40.00 |
| 52 Week High | $22.44 | $99.50 |
| Indicator | RUN | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 25.14 | 48.40 |
| Support Level | N/A | $70.29 |
| Resistance Level | $13.46 | $82.65 |
| Average True Range (ATR) | 0.62 | 3.35 |
| MACD | -0.24 | -0.48 |
| Stochastic Oscillator | 5.20 | 25.06 |
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.